Van Luan Pham
5PUBLICATIONS
8CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (5)
Sort by Publication Date:
|Oct 21, 2025
Optimizing afatinib dosage: enhancing treatment outcomes and minimizing toxicities in advanced EGFR-mutated non-small cell lung cancer patients in Vietnam.Cam Phuong Pham, Hung Kien Do, Anh Tu Do
|May 25, 2025
Excellent survival benefit achieved in patients with advanced-stage non-small cell lung cancer harboring the epidermal growth factor receptor-G719X mutation treated by afatinib: the real-world data from a multicenter study in Vietnam.Van Luan Pham, Cam Phuong Pham, Thi Thai Hoa Nguyen
|Oct 29, 2024
Efficacy and Tolerance of First-Line Afatinib in Elderly NSCLC Patients with EGFR Mutations in Vietnam: A Multicenter Real-World Study.Tu Anh Do, Hoa Thi Thai Nguyen, Phuong Cam Pham
|May 13, 2024
Real-world analysis of afatinib as a first-line treatment for patients with advanced stage non-small-cell lung cancer with uncommon EGFR mutations: a multicenter study in Vietnam.Van Luan Pham, Tuan Anh Le, Cam Phuong Pham
|Mar 08, 2021
Real-world analysis of the effect of gefitinib as a first-line therapy in patients with advanced non-small cell lung cancer with EGFR mutations.Pham Van Luan, Nguyen Dinh Tien, Nguyen Minh Hai
Pageof 1
